139 results about "Novel protein" patented technology

This invention discloses a milk protein containing composition comprising: at least one milk protein; at least a first protein; at least a second protein; and at least a linker comprising an amino acid sequence coded by nucleotide sequence which is at least 80% similar to sequences selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21

The present invention relates to modified Dda helicases which can be used to control the movement of analytes such as polynucleotides. The modified Dda helicases are used in analyte detection and characterisation. The present invention also relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore.

The present invention discloses a novel protein composition comprising a first protein or polypeptide selected from a specific group. The protein composition has a broad-spectrum and efficient treatment effect on inflammatory diseases. The invention also discloses a preparation method of the protein composition and application of the protein composition in preparation of medical implants, medical devices or drugs.

The utility model discloses a novel protein marker diagnostic kit for detecting the muscle injury degree, which comprises a detection kit for detecting the muscle injury degree and a dustproof cover assembled above the detection kit, the detection kit is provided with a detection port for dropping blood of a patient and a display port for displaying a diagnosis result, a reagent card for evaluating the muscle injury degree by detecting the concentration of a specific protein marker in the blood is arranged in the detection kit, and the detection end of the reagent card is located below the detection port. The display end of the reagent card is positioned below the display opening; a positioning opening for positioning the dustproof cover is formed above the detection kit, and a positioning block matched with the positioning opening is arranged in the dustproof cover. According to the utility model, the muscle injury degree of a patient can be detected by quickly reading the novel protein marker in the blood, so that an accurate diagnosis and treatment basis is provided for the treatment of the patient, the detection time of the patient is shortened, and the treatment cost is reduced.

Provided herein are compositions, systems, and methods for delivering an effector protein into a cell. The present disclosure, in some aspects, provide novel proteins delivering an effector protein into a cell. The novel proteins are supernegatively charged proteins derived from highly anionic proteins identified from the proteome (e.g., human proteome). The novel protein tags can be associated (e.g., covalently or nocovalently) with the protein to be delivered to facilitate delivery of the effector protein into a cell.

The invention relates to a cell line capable of stably expressing an orthogonal aminoacyl tRNA synthetase / tRNA pair, constructs an HEK293T cell line capable of stably expressing an EcTyr orthogonal aminoacyl tRNA synthetase / BsTyr tRNA pair and discloses a construction method of the cell line, and the construction method comprises the following steps: stably integrating the orthogonal EcTyr aminoacyl tRNA synthetase and BsTyr tRNA gene into an HEK293T cell genome by virtue of a PiggyBac transposon system and stable plasmid transfection; according to the constructed cell line genome, the EcTyr orthogonal aminoacyl tRNA synthetase and the BsTyr tRNA gene are integrated, so that a stable platform is provided for efficiently introducing non-natural amino acid at any site of protein. The method has the effect of further laying an experimental foundation for exploration of novel protein structures and functions and research and development of protein drugs with certain specific functions.

A target protein drug binding prediction method based on meta learning and subgraph matching, by constructing protein structure, drug small molecule structure and its binding energy value, the meta learning training task is established according to protein grouping, that is, as the main model of the meta model; the sub model and its loss function for the protein prediction task are obtained after fine tuning of the meta model; then the task self-adaptive self-attention model is established to balance the optimization contribution of the sub model of each protein prediction task to the meta model, the weighted average is used for the loss function of the sub model of each protein prediction task to obtain the meta model loss function; then the meta model loss function is used to calculate the gradient, the meta model parameters are updated and optimized based on the preset learning rate, and after the training is completed, the trained meta model is used for fine tuning of the test set of new protein samples, the prediction sub model of the new protein is obtained, the sub model is used for prediction of the protein test set, and the evaluation result is obtained. The training method combining meta learning and subgraph matching can effectively avoid shortcut learning, enhance the generalization effect, and also solve the problem that the previous prediction model is difficult to predict the newly discovered protein.

The present invention relates to modified recombinant agrin proteins or fragments thereof and recombinant chimeric laminin-nidogen proteins or fragments thereof, nucleic acid sequences encoding these proteins, vectors containing these nucleic acid sequences, compositions comprising these proteins, and the use of these proteins in the prevention and / or treatment of congenital muscular dystrophies, in particular (laminin-α2) LAMA2-associated muscular dystrophy.

The application discloses a novel protein separator capable of purifying water quality through bacteria and algae culture and automatically maintaining dynamic balance, which comprises a casing, a gas-water generating device connected to the bottom of the casing, a separation component and a bacteria and algae culture part located above the water level in the casing, a sewage outlet located above the separation component in the upper part of the casing, a water outlet in the lower part of the casing, the separation component comprising a conical pipe and a straight pipe connected in series, the inner diameter of the conical pipe gradually increasing from bottom to top, the lower end of the straight pipe being connected with the upper end of the conical pipe, the separation component having one or more vertical notches, and the upper end of the notch extending to the upper end of the straight pipe. The separation component is used for repeatedly enriching, concentrating and dewatering the pollutants, and the dynamic balance of the bacteria and algae in the equipment and the water body to be treated is realized through the bacteria and algae culture part, so that the volume of the separated pollutants can be greatly reduced, the concentration of the separated pollutants can be improved, and the separated pollutants can be utilized, which has positive significance for reducing the treatment cost of the pollutants and recycling the pollutants.

The invention provides a novel lysosomal targeting fusion protein based on fusion of an IGF2 mutant and an antibody, and a method for degrading a protein by using the novel protein construct.

The present application provides a novel protein or polynucleotide variant, a Corynebacterium glutamicum strain containing the protein or polynucleotide variant, and a method for producing L-lysine using the strain.

The present invention relates to novel protein arginine methyltransferase 5 (PRMT5) inhibitor compounds and methods for treating adenomatous polyposis coli (APC) loss-of-function driven adenoma diseases in a human in need thereof.

The invention discloses a novel protein structure prediction method based on AI, and particularly relates to the technical field of protein structure research, a protein amino acid sequence is converted into a multi-dimensional feature matrix, homologous fragment information is fused, and feature representation with physical and chemical properties and potential folding rules is obtained; extracting local residue relation and global sequence dependency information by combining graph convolution and a self-attention mechanism, constructing a multi-scale subsurface space, and realizing comprehensive description of a folding trend; candidate conformation generation and uncertainty indexes are introduced into the submerged space, and it is ensured that the prediction process has reliable quantization; ranking and screening the priorities of the candidate conformations in combination with an energy constraint function and structural similarity measurement, and outputting an optimized structure set with reasonable energy and coordinated trend; a prediction structure is generated through multi-modal information fusion, and credibility evaluation is performed, so that the problem that prediction accuracy and interpretability are difficult to consider at the same time in an existing method is effectively solved.

The present disclosure is generally related to recombinant microbial cells expressing heterologous proteins of interest. Certain aspects of the disclosure are therefore related to, inter alia, recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the instant disclosure are particularly suitable for use in the expression, production and secretion of heterologous proteins.

The invention discloses a SpaD-based polypeptide-protein reaction pair, and belongs to the technical field of protein engineering. The D2-D3 structural domain of the corynebacterium diphtheriae pilus protein SpaD is split into reaction pairs in two modes, the two parts can be efficiently recombined and react to generate isopeptide bonds, and covalent coupling is achieved. Wherein when the D2 structural domain is split into reaction pairs, a D214-T455 residue of an original sequence is a capturer protein (D2C), and an E182-K213 residue of the original sequence is a tag polypeptide (D2T); when the D3 structural domain is split into reaction pairs, the E182-D434 residue of the original sequence is a capturer protein (D3C), and the G438-T455 residue of the original sequence is a tag polypeptide (D3T). The reactivity of a reaction pair obtained by splitting D3 is equivalent to that of a common spy reaction pair, is not influenced by the position of a tag sequence, is orthogonal to the spy reaction pair and a probe reaction pair, is a novel protein coupling tool, and has a relatively high practical value in protein engineering.

The present disclosure relates generally to recombinant microbial cells expressing heterologous proteins of interest. Accordingly, certain aspects of the present disclosure relate, inter alia, to recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the present disclosure are particularly suitable for use in the expression, production, and secretion of heterologous proteins.

The present invention relates to novel proteins specific for programmed (cell) death ligand 1 (PD-L1). The PD-L1 specific protein of the present invention binds to human and mouse PD-L1 with high affinity. The present invention also relates to a PD-L1 specific protein further comprising a diagnostic or therapeutic active ingredient. Further aspects of the invention encompass the use of these PD-L1-specific binding proteins in medical treatment, for example in the diagnosis and treatment of PD-L1-related cancers.

The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.

Provided are methods for treating cancer by administrating to an individual who has the cancer an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD) and an immune checkpoint inhibitor. Also provided are methods for promoting translation of proteins within cells such that proteins include one or more misincorporated amino acids to thereby develop new proteins that contain neoantigens. Vaccines that include the neoantigens are included. Methods for producing and detecting misincorporation of a tyrosine in proteins expressed by cells are also provided.

Provided are a novel protein having histidine exporting activity. an L-histidine producing microorganism modified to express the protein. and a L-histidine producing method using the microorganism.

The present invention relates to a mutated SARS-COV-2 spike protein, a variant or fragment thereof or an mRNA or DNA encoding them for use in the prevention of COVID-19.

The utility model discloses a novel protein separation and extraction device which comprises a crushing mechanism and a separation mechanism, and the separation mechanism is arranged at the lower part of the crushing mechanism; the crushing mechanism comprises a first-stage cutting part, a second-stage crushing part and a third-stage grinding part which are sequentially arranged from top to bottom; the first-stage cutting part, the second-stage crushing part and the third-stage grinding part are communicated in sequence; a feeding opening is formed in the upper surface of the first-stage cutting part, and the crushing particle size of the second-stage crushing part is smaller than that of the first-stage cutting part. According to the utility model, three stages of grinding parts are arranged, and the plurality of grinding rollers are uniformly distributed on the driving shaft, so that intermittent grinding of materials is realized under the rotation action of the driving shaft, and the temperature in the grinding cavity is prevented from rising due to heat generated by high-speed friction between the grinding rollers and the grinding disc as well as between the grinding rollers and the materials; the temperature in the grinding cavity can be better stabilized, and a stable operation environment is provided for separation and extraction of vegetable protein.

The invention provides a novel protein degradation agent conjugate and a conjugate thereof. Specifically, the invention provides a protein binding conjugate or a pharmaceutically acceptable salt thereof, and the protein binding conjugate is as shown in a formula (I), wherein the variables are as defined herein, as well as pharmaceutical compositions containing the protein binding conjugates and uses thereof.

The present invention provides a novel protein and biologically-active fragments and variants thereof with advantageous therapeutic and cosmetic uses. Also provided are methods of using the proteins, as well as methods of producing the proteins using a recombinant cell. Further provided are recombinant host cells transformed with a polynucleotide sequence that encodes the expression of the proteins.

The application relates to a protein characterization learning method and device, computer equipment and a storage medium. The method comprises the following steps: collecting protein sequence, structure and function annotation information, and constructing a multi-modal feature data set; performing multi-modal feature extraction on the multi-modal feature data set by using a MASSA framework to obtain protein multi-modal representation; constructing a graph network by using the protein multi-modal representation, and storing the representation and a historical model of an existing protein task in the graph network; in the training process of a new protein task, a memory enhancement mechanism is used to retrieve a similar node of the new protein task from the graph network, a historical model of an existing protein task corresponding to the similar node is obtained, model parameters of the historical model are transferred by using a transfer learning framework, and model training is performed on the new protein task. The application effectively alleviates the data scarcity problem and improves the accuracy and generalization ability of the model in a small sample learning task.

Disclosed are a protein degrader targeting O-GlcNAc Transferase (OGT), and a preparation method therefor and a use thereof. The inventors of the present invention have creatively discovered that a compound recruits MDM2 by means of its interaction with nucleolin (NCL), and through further experiments have found that it can serve as a novel recruiting element for MDM2, which can be used in the preparation of targeted protein degraders and other applications. Using the above findings, the inventors have prepared a novel protein degrader compound targeting OGT, and have found through experimentation that the prepared targeted protein degrader can effectively induce the degradation of OGT, for use in the treatment of diseases mediated by OGT or associated with O-GlcNAc glycosylation (such as neurodegenerative diseases, obesity, tumors, diabetes and complications thereof, cardiovascular diseases, etc.), and will have very promising application prospects in the fields of medicine and health management.

The utility model relates to the technical field of gel filtration chromatography, in particular to a novel protein gel filtration chromatography column which comprises a filtration chromatography column body, a protection component, a feeding component and a filtrate guide outlet, the feeding component comprises a feeding hopper, a supporting rod is arranged on the inner side of the feeding hopper, a flow guide block is arranged on the lower side of the supporting rod, and the filtrate guide outlet is arranged on the lower side of the supporting rod. A discharging port is formed in the lower end of the feeding hopper, a rubber plug is arranged at the lower end of the outer side of the feeding hopper, a mounting frame is arranged on the outer side of the feeding hopper, a first sliding rod is arranged at the lower end of the mounting frame, and a first clamping ring is arranged on one side of the first sliding rod. According to the utility model, the material is guided through the feeding component, so that the material slides to the lower end of the filtering chromatographic column main body through the inner wall of the filtering chromatographic column main body to finish feeding, the collision among the materials is reduced, the generation of bubbles is reduced, the filtering chromatographic column main body is protected through the protection component, and the use safety is improved.

To provide a new serum marker whose expression is restricted to the latent form of toxoplasmosis (bradyzoites / cysts). Also provided is an antibody that specifically binds to the new protein.SOLUTION: The present invention relates to a new Toxoplasma gondii protein, hereinafter referred to as BCLA, a new serum marker whose expression is restricted to the latent form of toxoplasmosis. This specific protein and its antigenic fragments can be used to detect autoantibodies in the serum of patients for the diagnosis of latent forms of toxoplasmosis. The invention also relates to derived antibodies generated by BCLA immunization that specifically bind to this new protein.SELECTED DRAWING: None

The application relates to a cell line stably expressing an orthogonal aminoacyl tRNA synthetase / tRNA pair, a HEK293T cell line capable of stably expressing an EcTyr orthogonal aminoacyl tRNA synthetase / BsTyr tRNA pair is constructed, and a construction method of the cell line is disclosed. The construction method is to stably integrate the orthogonal EcTyr aminoacyl tRNA synthetase and BsTyr tRNA genes into the HEK293T cell genome by means of a PiggyBac transposon system and plasmid stable transfection. The constructed cell line genome is integrated with the EcTyr orthogonal aminoacyl tRNA synthetase and BsTyr tRNA genes, and provides a stable platform for efficiently introducing unnatural amino acids at any site of a protein. The application has the effects of further laying an experimental foundation for the exploration of novel protein structures and functions and the research and development of protein drugs containing certain specific functions.

The present application has an object to provide a novel protein cross-linking method. By allowing both an oxidoreductase such as laccase and a protein deamidase such as protein glutaminase to act on a substrate protein, a cross-linking reaction is promoted.